Arrowhead Research Corporation ARWR will host an analyst event today in New York City to discuss
ARC-520, its RNAi-based candidate designed to treat chronic hepatitis B
virus infection. The company will discuss the program and describe new
preclinical data showing that a low dose of ARC-520 induced rapid and
deep reductions in viral particles and key viral antigens in a
chimpanzee chronically infected with hepatitis B virus. Arrowhead
identified a well-tolerated dose of ARC-520 that lead to a 95% reduction
in circulating viral DNA, and approximately 90% reductions in hepatitis
e-antigen (HBeAg) and s-antigen (HBsAg), which are thought to be
important in establishing a functional cure. These data support previous
findings in rodent models and may be
See full press release
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in